Koers Biodexa Pharmaceuticals Plc London S.E.
Aandelen
BDRX
GB00BNGF1L75
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 4,58 mln. 5,71 mln. 5,36 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | - | Nettowinst (verlies) 2025 * | - | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 0 | Nettoliquiditeiten 2025 * | - 0 0 | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-
| K/w-verhouding 2025 * |
-
| Werknemers | 21 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 57,92% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Stephen Stamp
CEO | Chief Executive Officer | 62 | 09-09-19 |
Dan Palmer
CTO | Chief Tech/Sci/R&D Officer | - | - |
Chief Tech/Sci/R&D Officer | 44 | 11-07-21 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Stephen Parker
CHM | Chairman | 65 | 20-06-22 |
Sijmen de Vries
BRD | Director/Board Member | 65 | 29-10-14 |
Stephen Stamp
CEO | Chief Executive Officer | 62 | 09-09-19 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-3,46% | 102 mld. | |
+1,41% | 96,29 mld. | |
+2,13% | 22,18 mld. | |
-15,84% | 21,2 mld. | |
-9,21% | 18,31 mld. | |
-39,98% | 17,38 mld. | |
-14,65% | 16,36 mld. | |
+4,39% | 13,97 mld. | |
+31,35% | 12,17 mld. |